Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 1.00 |
| ▸ | HTR6 | P50406 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022433 | 1.00 | HTR7 (1.00) | HTR7HTR6HTR1AHTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL1673713 | 0.98 | HTR7 (0.96) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL941809 | 0.86 | HTR7 (1.00) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL7085636 | 0.84 | HTR7 (0.73) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL4914927 | 0.84 | HTR7 (0.73) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL4915187 | 0.84 | HTR7 (0.73) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL6560082 | 0.84 | HTR7 (0.73) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL14060577 | 0.82 | HTR7 (1.00) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL5352962 | 0.82 | HTR7 (0.69) | HTR7HTR6HTR1AHTR2AHTR5A | |
| SCHEMBL15834279 | 0.81 | ADRB1 (0.75) | HTR7HTR6HTR1AHTR2AHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778576-B1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | HANLIM PHARMACEUTICAL CO LTD (KR) | 2024-04-17 | — | — | EP | claimed |
| US-11299478-B2 | 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2022-04-12 | — | — | US | claimed |
| US-20210047301-A1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | HANLIM PHARMACEUTICAL CO., LTD. (KR) | 2021-02-18 | — | — | US | claimed |
| EP-3778576-A1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Hanlim Pharmaceutical Co., Ltd. (KR) | 2021-02-17 | — | — | EP | claimed |
| WO-2019190117-A1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 한림제약(주) | 2019-10-03 | — | — | WO | claimed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-12-26 | — | — | US | disclosed |
| EP-3778576-B1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | HANLIM PHARMACEUTICAL CO LTD (KR) | 2024-04-17 | — | — | EP | disclosed |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University-Of The Commonwealth System Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2000052001-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5780472-A | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAZL CO., LTD. (KR) | 1998-07-14 | — | — | US | disclosed |
| CN-1145620-A | New piperazine derivatives and its prepn. | SAMJIN PHARM CO LTD (KR) | 1997-03-19 | — | — | CN | disclosed |
| EP-0749425-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARM. CO., LTD. (KR) | 1996-12-27 | — | — | EP | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
| WO-1996021648-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | HTR7 269/4885HTR6 357/4885HTR1A 373/4885 |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | HTR7 1/4885HTR6 3/4885HTR1A 4/4885 |
| US-20210047301-A1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CTSK, CTSS, CTSZ | HTR7 4417/4885HTR6 4795/4885HTR1A 4870/4885 |
| US-11299478-B2 | 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same | CTSK, CTSS, CTSZ | HTR7 4417/4885HTR6 4795/4885HTR1A 4870/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | HTR7 269/4885HTR6 357/4885HTR1A 373/4885 |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | HTR7 1/4885HTR6 3/4885HTR1A 4/4885 |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | HTR7 1/4885HTR6 2/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.